Clinical Trial Update: Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults [Phase 1]

View source ↗

Summary

Phase 1 safety evaluation of a glycoprotein D vaccine (gD vaccine) for herpes simplex virus in HSV-positive healthy adults, with and without MPL adjuvant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Virus Infection

Drugs mentioned

• Monophosphoryl lipid A (MPL) adjuvant (Monophosphoryl lipid A)
• glycoprotein D vaccine (gD vaccine) (glycoprotein D vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Simplex | Phase 1 | Status: COMPLETED